Integra Lifesciences Holdings (IART) Net Income towards Common Stockholders (2009 - 2026)

Integra Lifesciences Holdings has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $4.5 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 100.93% year-over-year to $4.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.2 million (up 98.55% YoY) and the FY2025 annual result came in at -$516.5 million, down 7337.7% from the prior year.
• Net Income towards Common Stockholders climbed to $4.5 million in Q2 2026 per IART's latest filing, from -$4.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $52.9 million in Q4 2022 and troughed at -$484.1 million in Q2 2025.
• A 5-year average of -$15.3 million and a median of $4.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders slumped 3803.18% in 2025, then soared 100.93% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at $52.9 million in 2022, then plunged by 62.54% to $19.8 million in 2023, then dropped by 2.01% to $19.4 million in 2024, then sank by 108.77% to -$1.7 million in 2025, then soared by 363.03% to $4.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $4.5 million, -$4.6 million, and -$1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.